Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
741-760 of 1,307 trials

Alzheimer's Disease: Understanding Tau Spread and Language Function

We are studying how tau protein spreads in the brain during different stages of Alzheimer's disease and its impact on language abilities. This research may help us understand cognitive changes in patients.

Early Alzheimer's Disease>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesNeurologyPsychiatry

Prostate Cancer: PF-06821497 with Enzalutamide

We are studying a new treatment combining PF-06821497 with enzalutamide for men with advanced prostate cancer previously treated with abiraterone. The goal is to see if this combination can improve survival and reduce tumor activity compared to standard therapies.

Castration-resistant Prostate Cancer6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Multiple Sclerosis in Kids: Ofatumumab and Siponimod Study

We are comparing two new treatments, ofatumumab and siponimod, to fingolimod in children with multiple sclerosis. The study aims to see if these new options are as effective and safe for managing their condition.

Multiple Sclerosis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurologyPediatrics

High Blood Pressure: Irbesartan and Amlodipine Combination

We are testing a new fixed-dose pill combining irbesartan and amlodipine for patients with high blood pressure. The goal is to see if it effectively lowers blood pressure and is safe for use.

High Blood Pressure1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Adnexal Torsion: Contrast-Enhanced Ultrasound Study

We are testing a new ultrasound method to see if it helps diagnose adnexal torsion more accurately than standard methods. This could reduce unnecessary surgeries and improve care for patients with suspected torsion.

Adnexal Torsion>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsInternal Medicine

Semaglutide for Mood Improvement in Depression

We are studying if the medication semaglutide can help improve mood in people with major depressive disorder who are also overweight or obese. The trial will measure changes in depressive symptoms and overall well-being.

Unipolar DepressionObesity and Overweight6-12 monthsConfirmation phase (III)Monitoring phase (IV)Investigational MedicinesCost ReimbursementPsychiatry

Danicopan for Pediatric PNH Patients

We are studying whether adding danicopan to existing treatments helps children with Paroxysmal Nocturnal Hemoglobinuria improve their hemoglobin levels and quality of life.

Paroxysmal Nocturnal Hemoglobinuria3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyPediatrics

Fecal Microbiota Transplantation for Crohn’s Disease After Anti-TNF Withdrawal

We are studying whether fecal microbiota transplantation can help maintain remission in Crohn’s disease patients after stopping anti-TNF treatment. This trial compares FMT to a sham procedure to assess its effectiveness in preventing relapse and improving gut health.

Crohn's DiseaseConfirmation phase (III)Monitoring phase (IV)6-10 visitsInvestigational MedicinesGastroenterologyInternal Medicine

Relapsed Multiple Myeloma: Daratumumab Treatment Study

We are comparing two treatment strategies using Daratumumab, Lenalidomide, and Dexamethasone for patients with relapsed multiple myeloma. The goal is to see if a fixed treatment duration is as effective as continuous therapy.

Myeloma Recurrence>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Severe Infections in ICU: Comparing Antibiotics

We are studying whether piperacillin-tazobactam or temocillin can effectively treat severe infections caused by certain bacteria in ICU patients, compared to standard carbapenem treatment. This research may help improve treatment options for critically ill patients.

ESBL-Producing Bacteria Infection>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Type 1 Diabetes: Metformin's Impact on Arterial Health

We are studying whether metformin can slow down artery calcification and improve blood flow in people with type 1 diabetes who do not have chronic kidney disease. This research may help us understand how to better manage cardiovascular risks in these patients.

Vascular CalcificationType 1 Diabetes>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCardiologyEndocrinologyInternal Medicine

Antisynthetase Syndrome: Cyclophosphamide vs Tacrolimus

We are comparing the effects of Cyclophosphamide and Azathioprine against Tacrolimus in patients with antisynthetase syndrome-related lung disease. The goal is to see which treatment better improves lung function and quality of life.

Interstitial Lung DiseaseConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPulmonologyRheumatology

Fecal Microbiota Transfer for Diabetes Control After Bariatric Surgery

We are studying whether fecal microbiota transfer can help improve blood sugar levels in patients who had bariatric surgery and are in diabetes remission. This trial will explore its effects on insulin production and overall health.

Type 2 Diabetes>2 yearsConfirmation phase (III)Investigational MedicinesEndocrinologyInternal Medicine

Prurigo Nodularis: Povorcitinib Treatment Study

We are studying the effects of povorcitinib on itching and skin lesions in people with prurigo nodularis. The goal is to see if it improves symptoms and quality of life while ensuring safety.

Prurigo Nodularis1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Macular Telangiectasia Type 1: Aflibercept vs. Placebo

We are studying whether aflibercept can improve retinal thickness and vision in patients with macular telangiectasia type 1 compared to a placebo. The trial also looks at the safety of the treatment.

Macular Telangiectasia3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesOphthalmology

COPD Exacerbation: New Diagnostic Strategy

We are testing a new method using advanced diagnostics to see if it can help reduce antibiotic use during severe COPD flare-ups. This study compares this approach to standard treatment to evaluate its effectiveness and safety.

Severe COPD with Ventilation Support>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPulmonology

Dermatomyositis: Baricitinib Treatment Study

We are studying whether baricitinib can help patients with dermatomyositis improve without using steroids. This trial compares its effects to a placebo while providing usual care.

Dermatomyositis>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsStandard MedicinesDermatologyRheumatology

Pancreatic Cancer: FOLFOX vs. Gemcitabine

We are comparing two chemotherapy treatments, FOLFOX and gemcitabine, for patients with advanced pancreatic cancer who cannot tolerate a stronger regimen. The goal is to see which treatment works better and is safer for these patients.

Pancreatic Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Cardiovascular Risk Management: BIO-RISK-EVENT Study

We are testing a new approach to managing heart health in patients at high risk for heart events. The goal is to see if this intensified treatment is more effective than standard care.

Heart Attack>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Oxygen Therapy for Acute Pulmonary Embolism

We are investigating whether supplemental oxygen helps patients with intermediate-risk acute pulmonary embolism improve their health and reduce hospital stays. The study also looks at its effects on survival rates over time.

Acute Pulmonary Embolism>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyPulmonology